Cox Regression Methods for Two‐Stage Randomization Designs
暂无分享,去创建一个
[1] David A. Binder,et al. Fitting Cox's proportional hazards models from survey data , 1992 .
[2] P. Grambsch,et al. Modeling Survival Data: Extending the Cox Model , 2000 .
[3] P. Holland. Statistics and Causal Inference , 1985 .
[4] R. L. Prentice,et al. A case-cohort design for epidemiologic cohort studies and disease prevention trials , 1986 .
[5] Marie Davidian,et al. Estimation of Survival Distributions of Treatment Policies in Two‐Stage Randomization Designs in Clinical Trials , 2002, Biometrics.
[6] Z. Ying,et al. Cox Regression with Incomplete Covariate Measurements , 1993 .
[7] H. Senn,et al. Combined-modality treatment of small-cell lung cancer: Randomized comparison of three induction chemotherapies followed by maintenance chemotherapy with or without radiotherapy to the chest , 1994 .
[8] S. Gasparini,et al. Small cell lung cancer (SCLC): a randomized trial of cyclophosphamide, adriamycin, vincristine plus etoposide (CAV-E) or teniposide (CAV-T) as induction treatment, followed in complete responders by alpha-interferon or no treatment, as maintenance therapy. , 1994, Anticancer research.
[9] H. Sung,et al. Selecting Therapeutic Strategies Based on Efficacy and Death in Multicourse Clinical Trials , 2002 .
[10] D. Horvitz,et al. A Generalization of Sampling Without Replacement from a Finite Universe , 1952 .
[11] C Y Wang,et al. Augmented Inverse Probability Weighted Estimator for Cox Missing Covariate Regression , 2001, Biometrics.
[12] Randy D Gascoyne,et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] A. Tsiatis,et al. Optimal Estimator for the Survival Distribution and Related Quantities for Treatment Policies in Two‐Stage Randomization Designs in Clinical Trials , 2004, Biometrics.
[14] R. Gascoyne,et al. Rituximab-CHOP Versus CHOP with or without Maintenance Rituximab in Patients 60 Years of Age or Older with Diffuse Large B-Cell Lymphoma (DLBCL): An Update. , 2004 .